Home | Safety and efficacy of CIMAvax®-EGF in combination with tyrosine kinase inhibitors in patients with advanced stage Non-Small Cell Lung Cancer and EGFR mutations

The revisions let you track differences between multiple versions of a post.

To edit, publish or delete one of the revisions below, click on its saved date.

Published clinical_trials Safety and efficacy of CIMAvax®-EGF in combination with tyrosine kinase inhibitors in patients with advanced stage Non-Small Cell Lung Cancer and EGFR mutations has 2 revisions.
RevisionStatus
Saved 15/06/2021 - 9:31am by lazara
current revision (published)
Saved 22/05/2021 - 6:24pm by Gladys
archived